Carisma Therapeutics Inc. ("Carisma" or the "Company"), a leader in macrophage-focused therapeutics, today announced that Steven Kelly, President and Chief Executive Officer, will participate in the ...

Zevra to receive a 2025 New Treatment Award for MIPLYFFA™ at the 21st Annual WORLDSymposiumEight abstracts discussing data and clinical ...

The global enzyme replacement therapy market size was valued at USD 10.12 billion in 2024 and is projected to grow from USD 11.35 billion in 2025 to reach USD 21.29 billion by 2033, exhibiting a CAGR ...

Julien Grogg, PhD, MBA - CEO of Release Therapeutics Release Tx logo Dr. Julien Grogg will Lead the Company's Transition to Clinical ...

Our work extends the application of this motif to enzymes specific to the lysosomal compartment and relevant to genetic diseases affecting ... of correction for storage pathology in the spleen ...

BizClik, the UK's fastest-growing publishing company, has published the latest editions of Supply Chain Digital and Procurement Magazine. These publications are highly regarded within the supply chain ...

Patient advocacy groups warned that delays in implementing India's rare disease policy have left many, including children, in ...

Featured data showcase the transformative potential of HSC gene therapy to enable cross-correction and restore enzymatic ...

The firm will begin testing a second dose cohort with AMT-191 after receiving a positive recommendation from a data monitoring committee.

Chiesi GRD has an initial focus in developing therapies for lysosomal storage disorders (LSDs), including Fabry disease, as well as other rare diseases in haematology and opthalmology indications.

Denali Therapeutics (NASDAQ:DNLI – Free Report) had its target price trimmed by The Goldman Sachs Group from $45.00 to $40.00 in a research report sent to investors on Tuesday morning,Benzinga reports ...